Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab

Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis

Shilpa Medicare receives US approval for Varenicline Tablets, 0.5 mg and 1 mg

Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)

Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority

Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws

Metropolis to acquire Dehradun’s Ahujas’ Pathology & Imaging Centre for Rs. 35.01 Cr

Fluor to provide EPCM services for pharmaceutical facility in Indiana

This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202

Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development

This collaboration positions WACKER and RNAV8 as premium mRNA service providers

Mankind unveils HealthOK’s 100% vegetarian multivitamin tablets campaign with Archana Puran Singh

Emcutix and WiQo sign licensing partnership for derma-cosmetic treatments in India

PRX-PLUS has a unique product feature with its deep-impacting formula

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy